Zobrazeno 1 - 10
of 61
pro vyhledávání: '"Christine Guelcher"'
Publikováno v:
The Journal of Haemophilia Practice. 8:86-97
The management of patients with haemophilia is complex and requires lifelong care to be delivered by a specialist multidisciplinary team. Haemophilia B results from a deficiency or absence in coagulation factor IX (FIX), leading to easy bruising, and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b71d51c8c4f11026fbadc28b5cc75ae7
https://doi.org/10.17225/jhp00180
https://doi.org/10.17225/jhp00180
Publikováno v:
Haemophilia. 27:82-86
Over the last several decades, the increasing focus on women with inherited bleeding disorders (WBD) has brought more patients into Haemophilia Treatment Centres (HTC) around the world. These women present with unique challenges including a significa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7c40eeb0e3b0538b675da721e6750b4e
https://doi.org/10.1111/hae.14019
https://doi.org/10.1111/hae.14019
Autor:
Lance Ballester, Christine Guelcher, Isabella McCary, Jan G. Kuhn, Gita Massey, Michael F. Guerrera, Leslie Raffini, Regina Butler
Publikováno v:
Haemophilia. 26:631-636
INTRODUCTION Emicizumab is a recombinant humanized bispecific antibody that bridges factor IXa and factor X to mimic the cofactor function of factor VIII. It is approved to prevent bleeding in patients with haemophilia A (HA). Outside of clinical tri
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0919b1cd2f9d18a9378b5626e9daae3b
https://doi.org/10.1111/hae.14005
https://doi.org/10.1111/hae.14005
Autor:
Tewarit Sarachana, Neetu Dahiya, Vijaya L Simhadri, Gouri Shankar Pandey, Surbhi Saini, Christine Guelcher, Michael F Guerrera, Chava Kimchi-Sarfaty, Zuben E Sauna, Chintamani D Atreya
Publikováno v:
PLoS ONE, Vol 10, Iss 7, p e0132433 (2015)
Hemophilia A (HA) is a bleeding disorder caused by deficiency of functional plasma clotting factor VIII (FVIII). Genetic mutations in the gene encoding FVIII (F8) have been extensively studied. Over a thousand different mutations have been reported i
Externí odkaz:
https://doaj.org/article/503b9832d77043658b43b0c844141a69
Autor:
Dawn Rotellini, Susan Hunter, Susan Cutter, Christine Guelcher, Spencer Dunn, David L. Cooper
Publikováno v:
Patient Related Outcome Measures. 10:257-266
Background The B-HERO-S study evaluated the impact of mild to severe hemophilia B on the lives of affected adults and children. Here, we assessed the impact of hemophilia B on relationships. Methods US adults with hemophilia B and caregivers of affec
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::924862925bc5fbabe662cfdb3cd055d0
https://doi.org/10.2147/prom.s214188
https://doi.org/10.2147/prom.s214188
Autor:
Leslie Raffini, Benjamin J. Samelson-Jones, Michael F. Guerrera, Jan G. Kuhn, Gita Massey, Regina Butler, Christine Guelcher
Publikováno v:
Haemophilia : the official journal of the World Federation of HemophiliaREFERENCES. 27(4)
Introduction Emicizumab is the first approved non-factor therapy for haemophilia A. It provides superior prophylactic bleeding control compared to other products in both patients with and patients without inhibitors. However, there is no real-world d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0b03bbd3c177670d9c9f2a95c126e5bb
https://pubmed.ncbi.nlm.nih.gov/34050689
https://pubmed.ncbi.nlm.nih.gov/34050689
Autor:
Craig M. Kessler, Tyler W. Buckner, David L. Cooper, Michelle Witkop, Robert F. Sidonio, Wendy E. Owens, Christine Guelcher, Neeraj N. Iyer, Moshe Fridman, David B. Clark
Publikováno v:
European Journal of Haematology. 101:781-790
Objective To assess the reliability and validity of six patient-reported outcomes (PRO) instruments for evaluating health-related quality of life in adults with mild-severe hemophilia B and caregivers of children with hemophilia B, including affected
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0827bff0446fa05881d5d6372a34601b
https://doi.org/10.1111/ejh.13168
https://doi.org/10.1111/ejh.13168
Autor:
Michael Recht, Wendy E. Owens, Neeraj N. Iyer, Skye Peltier, Mary Jane Frey, Tyler W. Buckner, Susan Hunter, Michelle Rice, Natalia Holot, David L. Cooper, Michelle Witkop, Christopher E. Walsh, Christine Guelcher, David B. Clark, Robert F. Sidonio, Neil Frick, Craig M. Kessler
Publikováno v:
European Journal of Haematology. 98:5-17
The Bridging Hemophilia B Experiences, Results and Opportunities Into Solutions (B-HERO-S) initiative was launched in an effort to address specific gaps in the understanding of the psychosocial impact of mild-moderate-severe hemophilia B. The origina
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4098992325991225f7526ef95672d0ee
https://doi.org/10.1111/ejh.12854
https://doi.org/10.1111/ejh.12854
Publikováno v:
The Journal of Haemophilia Practice. 4:14-21
Introduction: As the focus on personalised treatment is refined, more products are brought to market and the life expectancy of persons with haemophilia increases, there will be an expanded need of experienced and expert healthcare providers to ensur
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7381e77e3db0ab20b56477d187bb3675
https://doi.org/10.17225/jhp00101
https://doi.org/10.17225/jhp00101
Autor:
Christine Guelcher, Janna M. Journeycake, Cliff Takemoto, Ellis J. Neufeld, Margaret V. Ragni, Robert F. Sidonio, Michael Recht, Dunlei Cheng, Jorge Caicedo, Michael D. Tarantino, Michael Denne, Susan Lattimore
Publikováno v:
Blood. 136:17-18
Introduction: It is anticipated that many patients with hemophilia are likely to switch from one coagulation factor product to a newer agent within the next few years. New replacement factor formulations have been developed using several approaches t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5de8f1274e8a13a964d9ee6337f45ed5
https://doi.org/10.1182/blood-2020-138898
https://doi.org/10.1182/blood-2020-138898